California Voters Will Have Their Say On Drug Prices
Heated battle expected over November ballot proposal to curb state’s prescription drug costs, as pharmaceutical industry opens its pocketbook to defeat the measure.
The independent source for health policy research, polling, and news.
681 - 693 of 693 Results
Heated battle expected over November ballot proposal to curb state’s prescription drug costs, as pharmaceutical industry opens its pocketbook to defeat the measure.
Experimental drugs might help desperate patients, but don’t count on an easy cure.
Some medicines, particularly intravenous treatments, are not listed in plans’ pharmacy benefit section and, therefore, it’s difficult to confirm coverage specifics.
Treating Hep C is expensive, but new drugs can quickly cure the disease, ultimately saving money.
The advocacy arm of the American Cancer Society said Wednesday that federal and state governments should move to restrict insurers from charging patients a percentage of the cost of their prescription drugs.
Only 16 percent of the popular plans cover all 10 of the most common drug regimens and charge less than $100 a month in consumer cost sharing, according to a report by Avalere Health.
Because of the complexity of insurance available through healthcare.gov and state exchanges, and the broad variation in how prescription drugs are covered, experts encourage consumers to compare options to figure out which one best fits their needs.
For beneficiaries, staying in their current plans could prove costly so advocates urge them to check out the alternatives.
Lawmakers, insurers and others have floated proposals to combat the spike in prescription drug prices, but will any of them gain traction?
Enrollment for private Medicare Advantage and Part D drug plans begins Oct. 15 and consumer advocates urge seniors to check out prices to find the best deals.
To control costs, the nation's largest pharmacy benefits manager has in place strict rules on which patients will be eligible.
The Democratic president candidate’s proposals to save consumers money are questioned by experts and health industry officials.
In an analysis, the Institute for Clinical and Economic Review concluded that price cuts are needed to control the budgetary impact.
© 2026 KFF